Bausch Health has a total of 10722 patents globally, out of which 4888 have been granted. Of these 10722 patents, more than 21% patents are active. United States of America is where Bausch Health has filed the maximum number of patents, followed by Europe and Japan. Parallelly, United States of America seems to be the main focused R&D centre and Canada is the origin country of Bausch Health.
Bausch Health was founded in the year 1959. The Company discovers and distributes pharmaceutical. The Company develops drugs for unmet medical needs in central nervous system disorders, eye health and gastrointestinal diseases, as well as contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic devices. As of April 2023, the market cap of Bausch Health is $2.93 Billion.
Do read about some of the most popular patents of Bausch Health which have been covered by us in this article and also you can find Bausch Health patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Bausch Health patent portfolio.
How many patents does the founder and the CEO of Bausch Health have?
The founder Milan Panic has 2 patents and CEO Thomas J. Appio has 0 patent.
How many patents does Bausch Health have?
Bausch Health has a total of 10722 patents globally. These patents belong to 2378 unique patent families. Out of 10722 patents, 2304 patents are active.
How Many Patents did Bausch Health File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Bausch Health Applications Filed | Bausch Health Patents Granted |
| 2023 | 1 | 12 |
| 2022 | 39 | 84 |
| 2021 | 81 | 79 |
| 2020 | 117 | 126 |
| 2019 | 103 | 107 |
| 2018 | 71 | 142 |
| 2017 | 72 | 191 |
| 2016 | 115 | 174 |
| 2015 | 64 | 168 |
| 2014 | 190 | 248 |
| 2013 | 327 | 341 |
| 2012 | 270 | 389 |
Which Bausch Health Drug Patents are Expiring in the Next 10 Years?
The patent no. US9662394B2 which is expiring in Oct, 2034, this invention offers stable compositions for treating fungal infections, including efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid.
Given below is the list of few drugs patented by Bausch Health accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Jublia | US9662394B2 | Stabilized Efinaconazole Compositions | Oct, 2034 |
| Zyclara | US8299109B2 | Method Of Treating Actinic Keratosis… | Dec, 2029 |
| Solodyn | US7919483B2 | Method For The Treatment Of Acne | Mar, 2027 |
| Aplenzin | US7572935B2 | Modified Release Formulations Of… | Jun, 2026 |
| Acanya | US10220049B2 | Topical Pharmaceutical Formulations… | Jun, 2029 |
Interested in knowing about Bausch Health Drug Patents Expiring in the next 10 years?
How many Bausch Health patents are Alive/Dead?
How Many Patents did Bausch Health File in Different Countries?
Countries in which Bausch Health Filed Patents
| Country | Patents |
| United States Of America | 1957 |
| Europe | 1047 |
| Japan | 737 |
| Australia | 598 |
| Germany | 591 |
| Canada | 577 |
| China | 548 |
| Spain | 433 |
| Korea (South) | 364 |
| Hong Kong (S.A.R.) | 362 |
| Mexico | 261 |
| Brazil | 222 |
| India | 213 |
| Singapore | 201 |
| Austria | 201 |
| Taiwan | 171 |
| Poland | 122 |
| Argentina | 80 |
| South Africa | 78 |
| Denmark | 53 |
| New Zealand | 49 |
| Indonesia | 49 |
| Portugal | 46 |
| United Kingdom | 46 |
| Israel | 45 |
| Hungary | 44 |
| Russia | 42 |
| Norway | 38 |
| Malaysia | 38 |
| Italy | 36 |
| Slovenia | 26 |
| Croatia | 23 |
| Cyprus | 20 |
| Czech Republic | 16 |
| Chile | 15 |
| Costa Rica | 14 |
| Peru | 12 |
| Slovakia | 11 |
| Serbia | 10 |
| Yugoslavia/Serbia and Montenegro | 9 |
| Philippines | 9 |
| Malta | 9 |
| Georgia | 9 |
| Ecuador | 8 |
| Colombia | 8 |
| Ukraine | 7 |
| Ireland | 7 |
| Uruguay | 5 |
| Nicaragua | 5 |
| France | 4 |
| Bolivia | 4 |
| Turkey | 4 |
| Viet Nam | 4 |
| Saudi Arabia | 4 |
| Dominican Republic | 4 |
| Lithuania | 3 |
| Eurasia | 3 |
| Panama | 2 |
| Belize | 2 |
| Tunisia | 2 |
| Finland | 2 |
| Uzbekistan | 2 |
| Latvia | 2 |
| Luxembourg | 2 |
| Albania | 2 |
| Montenegro | 2 |
| Macao | 2 |
| Iceland | 2 |
| Africa | 1 |
| Switzerland | 1 |
| United Arab Emirates | 1 |
| Netherlands | 1 |
| Greece | 1 |
| Morocco | 1 |
| Belgium | 1 |
| Gulf Cooperation Council | 1 |
| Africa | 1 |
Where are Research Centres of Bausch Health Patents Located?
10 Best Bausch Health Patents
US6413255B1 is the most popular patent in the Bausch Health portfolio. It has received 1211 citations so far from companies like Standen, Thermage and Cardima.
Below is the list of 10 most cited patents of Bausch Health:
| Publication Number | Citation Count |
| US6413255B1 | 1211 |
| US8180458B2 | 1028 |
| US6350276B1 | 880 |
| US6358263B2 | 761 |
| US8142200B2 | 736 |
| US6430446B1 | 664 |
| US6425912B1 | 608 |
| US6749624B2 | 552 |
| US20040206365A1 | 518 |
| US6381498B1 | 510 |
How many inventions of other companies were rejected due to Bausch Health patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Bausch Health invention. They couldn’t because Bausch Health had protected those before them.
Examiners at the USPTO referred 780 Bausch Health patents in 4120 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Bausch Health patent portfolio are Alcon, Bank of New York and Barclays Bank.
List of the Companies whose Patents were rejected citing Bausch Health –
| Company | Number of Patent Applications that faced Rejection Citing Bausch Health Patents | Number of Rejections (102 & 103) |
| Alcon | 108 | 296 |
| Bank of New York | 76 | 253 |
| Barclays Bank | 56 | 140 |
| Johnson & Johnson Vision Care | 54 | 146 |
| Amo Development | 27 | 48 |
| Carl Zeiss Meditec | 22 | 70 |
| Syneron Medical | 20 | 61 |
| Philips | 19 | 49 |
| Novartis | 18 | 43 |
| Katalyst Surgical | 18 | 35 |
Count of 102 and 103 Type Rejections based on Bausch Health Patents
Top Bausch Health Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US6413255B1 | 35 |
| US20040206365A1 | 22 |
| US7241805B2 | 20 |
| US7390089B2 | 20 |
| US20050049582A1 | 19 |
| US8475507B2 | 17 |
| US8426457B2 | 16 |
| US9492272B2 | 14 |
| US7282060B2 | 14 |
| US7130835B2 | 14 |
| US8579887B2 | 13 |
| US20100055133A1 | 13 |
| US7006874B2 | 13 |
| US8702691B2 | 12 |
| US6572608B1 | 12 |
What Percentage of Bausch Health US Patent Applications were Granted?
Bausch Health (Excluding its subsidiaries) has filed 748 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 647 have been granted leading to a grant rate of 93.77%.
Below are the key stats of Bausch Health patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Bausch Health?
| Law Firm | Total Applications | Success Rate |
| Bausch & Lomb Incorporated | 242 | 98.31% |
| Thompson HineBausch | 89 | 87.65% |
| Mccarter & English | 85 | 75.32% |
| Bausch Health Kilpatrick Townsend & Stockton | 79 | 98.44% |
| Saul Ewing Arnstein & Lehr | 45 | 100.00% |
| Hse Valeant | 21 | 87.50% |
| Oblon Mcclelland Maier & Neustadt | 16 | 100.00% |
| Valeant Pharmaceuticals International | 10 | 90.00% |
| Bass Berry & Sims | 9 | 62.50% |
| Michael E Carmen | 9 | 100.00% |